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Surgically unresectable advanced pancreatic cancer (APC) has an
extremely poor prognosis and is often highly symptomatic. The
unfavourable outcome of APC has not been substantially modified
by systemic treatment. 5-Fluorouracil (5-FU)-based chemotherapy
has been extensively used in APC. A variety of different schedules
and regimens have been evaluated and consistent anti-tumour
activity has been reported in a minority of patients. Symptomatic
relief was not readily assessed in the majority of these studies
(Crown et al, 1991; Rubin et al, 1996). Gemcitabine (2¢2¢-difluor-
deoxycytidine) is a deoxycytidine analogue with high activity in
preclinical models of solid tumours and in human cloning assays
(Von Hoff, 1996). Gemcitabine has anti-tumour clinical activity in
lung cancer and pancreatic cancer. In the latter tumour, gem-
citabine produces an 11% response rate and symptomatic relief in
a substantially larger percentage of patients (Burris et al, 1995;
Noble and Goa, 1997). New criteria of treatment effectiveness
have been recently defined in APC considering that (a) the stan-
dard activity criteria based on tumour regression are difficult to
assess in the case of retroperitoneal disease and massive liver
involvement, and (b) APC is often highly symptomatic with a
rapid decline in performance status. Improvement of survival does
not appear an easy task, based on the use of currently available
drugs. The clinical benefit response (CBR) criteria have been
designed for reproducible evaluation of gemcitabine activity in
APC. CBR is defined as a structured algorithmic approach which
is based on the composite measure of symptomatic improvement
based on pain intensity, analgesic consumption, performance
status and weight (Carmichael, 1997; Stephens, 1998). Burris et al
have demonstrated that gemcitabine produced an increase in CBR
and survival if compared to 5-FU in a randomized prospective trial
(Burris et al, 1995). We have approached the treatment of APC
combining gemcitabine with 5-FU given by continuous infusion.
The rationale of this combination was based on the contemporary
use of the two drugs that show anti-tumour activity in APC.
Moreover, the use of gemcitabine and 5-FU was allowed by the
different toxicity profile and by the potential advantages of
combining two nucleoside inhibitors. The continuous infusion
modality for 5-FU should reduce myelotoxicity, prolong thymidi-
late synthetase inhibition and increase the chance of pharmaco-
dynamic interactions with gemcitabine. The study was based on
the Simon’s two-stage optimal design and accrual could be
continued to the second stage only if a predetermined number of
responses should be reached on the first stage based on a prede-
fined target activity (Simon, 1989). CBR was selected as the
primary end point for this study.
PATIENTS AND METHODS
Patient accrual
Consecutive patients with histologically confirmed locally
advanced or metastatic APC were eligible. Symptomatic disease
was defined according to the following stringent criteria:
a. a performance status < 70 according to Karnovsky in the
absence of concurrent illness
b. pain requiring analgesia on a daily basis; pharmacologic treat-
ment should be quantified as morphine equivalent (equalized
to mg/day morphine consumption)
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c. Baseline pain intensity score of > or 20 mm (of a possible
100 mm on the Memorial Pain Assessment Card)
d. loss of > 10% of body weight.
Only patients with at least one assessable criterium were
considered for accrual. Adequate organ function with creatinine
< 2.0 mg dl–1, bilirubin < 1.5 mg dl–1, serum albumin > 2.5 mg dl–1,
transaminases < 2.5 ´ the upper limit of institutional standards,
baseline absolute neutrophil count (ANC) > 1500 ml–1 and platelet
count > 100 000 ml–1 were required. Patients with a PS < 50 or a
life expectancy of < 3 months could not be included in the study.
Additional exclusion criteria were symptomatic heart disease and
central nervous involvement. After approval, all patients gave
informed consent according to bioethical requirements.
Treatment
Gemcitabine-hydrochloride (Gemzar, Eli Lilly) was administered
by intravenous (i.v.) bolus injection at the dose of 1000 mg m–2 on
days 1, 8 and 15, and 5-FU (Roche) was given by continuous i.v.
infusion on days 1–5 at the daily dose of 500 mg m–2. Central
venous catheters (CVC) were inserted in all patients. Treatment
was repeated every 28 days. In the case of persistent neutropenia
(ANC < 1000 ml–1) or thrombocytopenia (platelets < 100 000 ml–1),
treatment was delayed until recovery to ANC > 1500 ml–1 and
platelets ³ 150 000 ml–1. A 50% gemcitabine and 50% 5-FU dose
reduction was planned in the case of ANC 500–1000 ml–1 and
platelets 50 000–100 000 ml–1 after 2 weeks delay. Colony stimu-
lating factors (CSFs) were not included in the study design and
could be considered only in the case of neutropenic fever or persis-
tent grade 4 neutropenia. A pain stabilization lead in period
of 7 days was allowed before beginning treatment for an accurate
determination of basal values.
Study design
A single institution phase II study was prospectively projected
according to the Simon’s two-stage optimal design (Simon, 1989).
According to this design a number (n1) patients are entered in the
first stage of the trial. The accrual continues to a total of n2
patients only if a specified r1 response rate is achieved in the first
series. A target activity of 25% response rate with a lower activity
of 5% have been selected, with a 0.05 a error and a 0.20 b error. In
this case the treatment under investigation should be considered
non-active if it produced no responses out of nine consecutive
patients in the first series and fewer than 4/30 patients in the
overall series. Taking into account the specific features of APC,
the primary end point of the study was the achievement of a CBR
according to the previously described criteria and to the definition
of toxicity profile (Burris et al, 1995; Carmichael, 1997; Noble et
al, 1997; Stephens, 1998). Anti-tumour activity as defined by the
standard criteria of tumour regression was the secondary end point
of the study. Assessment of CBR was performed weekly according
to the structured algorithm which has been developed in order to
provide an alternate end point in clinical trials of symptomatic
APC (Figure 1). An improvement of 50% from baseline provided
a positive score for pain intensity, while a 50% reduction of basal
analgesic consumption was classified as a positive response on
this latter parameter. The algorithm considers change in pain,
evaluated as changes in pain intensity and in analgesic consump-
tion and changes in performance status as the primary measures of
clinical benefit. A patient was classified positive on Karnovsky
Performance Status (KPS) if showed an improvement of at least
20 points over the baseline maintained for at least 12 weeks.
Change in weight is considered the secondary measure of clinical
benefit and an increase of 7% over the baseline was considered as
a positive response. CBR was designed in order to identify an
improvement more than the stabilization of disease-related symp-
toms. Time to loss of CBR (TTL-CBR) was calculated as the time
from beginning of chemotherapy to the loss of symptomatic
improvement induced by the treatment. A pretreatment clinical
evaluation was performed and was repeated every 3 weeks.
Imaging procedures (CT scan, ultrasound and/or nuclear magnetic
resonance) were routinely performed before starting treatment and
every 6 weeks thereafter. Additional procedures were allowed at
clinical judgement. Disease progression confirmed by imaging
procedures allowed determination of progression-free survival
(PFS). Tumour response was defined under the standard criteria.
RESULTS
Eleven consecutive patients with symptomatic APC were entered
into the study and all were considered on intention-to-treat
analysis; six patients were male and five female with a median age
of 60.5 years (range 37–76). All patients had intra-abdominal
disease. Liver metastasis were detected in 5/11 (45.4%) patients. A
median of 5 monthly courses were given (range 3–8). Seven out of
11 (63.6%) patients were responders on pain assessments: four
patients were classified positive both on pain intensity and anal-
gesic consumption, two patients were positive on pain intensity
and stable on analgesic consumption, one patient was positive on
analgesic consumption and stable on pain intensity. In addition,
three patients were stable on both parameters and only one patient
presented worsening of pain and required an increase of analgesic
dosage (Table 1A). Primary measures determination was subse-
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pain were assessed for KPS improvement. All patients classified
positive on pain were also positive or stable for KPS. Seven out of
11 patients were therefore classified positive on primary measures
and three were considered stable (Table 1B). Patients positive on
primary measures were considered clinical benefit responders.
Evaluation of body weight changes did not alter the CBR rate
because none of the patients who were stable on primary measures
showed a positive weight change and could be reclassified as
clinical benefit responders (Table 1C). In conclusion, a CBR was
experienced by 7/11 (63.6%) APC patients. This result exceeded
the projected response rate and the gemcitabine/5-FU combination
could be considered to provide a positive result on the primary
endpoint of our trial. Under the standard tumour imaging criteria,
1/11 (9.09%) PR was achieved, while stable disease was recorded
in 5/11 (45.4%), (Table 2). TTL-CBR could be a surrogate end
point which should be considered a substitute for PFS in clinical
benefit-oriented studies. In our study the mean duration of TTL-
CBR was 26.5 weeks (range 14–48, median 22). The gemc-
itabine/5-FU combination was well tolerated and no APC patient
experienced grade 3 toxicity. Grade 2 diarrhoea occurred in 2/11,
grade 2 nausea and vomiting in 2/11 and grade 2 neutropenia in
5/11 patients. (Table 3) Neutropenic fever was never recorded and
CSFs were not required in this series of patients. The insertion of a
CVC did not cause major complications.
DISCUSSION
Our study demonstrates that the gemcitabine/5-FU combination
under this schedule and dosages is well tolerated and induces
symptomatic relief in the majority of APC patients. CBR was
achieved in 7/11 (63.6%). The strict requirement for the CBR
determination under a structured algorithm looks for a positive
effect more than stabilization of the pre-existing status
(Carmichael, 1997; Stephens, 1998). The CBR is, therefore, an
effectiveness measure which appears suitable also as an end point
for phase II trials in highly symptomatic APC. It is important to
consider that only a major response under the standard criteria of
tumour regression was observed in our study, and the gem-
citabine/5-FU combination would have been rejected as inactive if
the study had been designed with the standard response criteria as
the primary end point. The CBR rate (7/11, 63.6%) which has been
achieved in the first phase of a two-stage design, exceeded the
minimal requirement (4/30) for demonstrating activity in the
series, suggest that the final validation phase (second stage
according to the Simon’s design) could be performed as the exper-
imental arm of a prospectively randomized study where gem-
citabine monochemotherapy should be considered as the standard
control arm. It has been reported that APC patients treated with
gemcitabine alone achieved CBR in the 24% of cases and with 5-
FU in the 5%. In this way the subsequent phase of gemcitabine/5-
FU evaluation should benefit from the randomization process in
order to avoid the phase II selection bias and over-estimation of
results. Overall survival should become the primary end point with
CBR and TTL-CBR as the secondary end points. Data on TTL-
CBR have been compared with the conventional end point of PFS
based on clinical evaluation and tumour imaging. In our series of
Table 2 Response to treatment
CR (%) 0/11 CBR (%) 7/11 (63.6)
PR (%) 1/11 (9.09)
SD (%) 5/11 (45.4)
DP (%) 5/11 (45.4)
PFS TTL-CBR
Mean (range) 31.4 (16–44) 26.5 (14–48)
Median 40 22
CR, complete remission; PR, partial remission; SD, stable disease; DP,
disease progression; CBR, clinical benefit response; PFS, progression-free
survival; TTL-CBR, time to loss of clinical benefit response.
Table 3 Number of patients who experienced toxic effects to
gemcitabine/5-fluorouracil
Number of patients (%)
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Rash 2 (18.18)
Fever 4 (36.36)
Nausea/vomiting 2 (36.36) 2 (36.36)
Fatigue 1 (9.09)
Diarrhoea 1 (9.09) 2 (36.36)
Neutropenia 1 (9.09) 2 (36.36)
Table 1 Clinical Benefit Response assessment in the phase II study
(number of patients)
(A) Pain intensity
Positive Stable Negative Total
Analgesic Positive 4 1 0 5
Consumption Stable 2 3 0 5
Negative 0 0 1 1







Positive Stable Negative Total
Pain Positive 2 5 0 7
Stable 0 3 0 3
Negative 0 0 1 1







Positive Stable Negative Total
Weight Positive 4 0 0 4
Non responsive 3 3 1 7
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patients TTL-CBR, based on weekly assessment, provided earlier
evidence of loss of therapeutical benefit as compared to the PFS;
TTL-CBR mean was 26.5 weeks (range 14–48), while mean PFS
was 31.4 weeks (range 16–44). Additional comparison between
the two end points has now to be performed in larger series of APC
patients. Quality of life assessment by standard approach such as
the EORTC QLQ C-30 questionnaire should be also performed in
parallel and provide a comparative analysis to CBR definition by
the structured algorithm (Aaranson et al, 1993). The relationship
between symptom relief and quality of life needs to be evaluated
in a prospective trial. It is important to consider that parallel phase
I–II studies of a similar combination where 5-FUu was given
together with gemcitabine reported a 38.46–66% CBR demon-
strating the highly symptomatic activity of this combination
(Cascinu et al, 1997; Hidalgo et al, 1997). Notably the highest
activity is reported when 5-FU was given by continuous i.v. infu-
sion on days 1–5 at the daily dose of 500 mg m–2. In conclusion
our results indicate that gemcitabine/5-fluorouracil deserves
further investigation and should be compared to standard gemc-
itabine monochemotherapy. Our findings underscore the need of
alternate effectiveness end points in symptomatic tumours as APC
were tumour regression and long-term survival are unlikely under
the presently available therapeutic approaches.
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